Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors
- PMID: 18513579
- DOI: 10.1016/S0169-5002(08)70100-4
Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors
Abstract
The epidermal growth factor receptor (EGFR) has been implicated in the pathophysiology of various cancers, including non-small cell lung cancer (NSCLC). Inhibitors targeting the tyrosine kinase domain of this receptor have been seen to elicit favourable responses in a subset of NSCLC patients. Mutational analysis of the EGFR has revealed that the response to reversible tyrosine kinase inhibitors (TKIs) is a result of the presence of activating mutations present between exons 18 and 21, most frequently the exon 19 deletion and the L858R mutations. After a prolonged treatment with reversible TKIs, patients have been seen to develop resistance that results, in part, from the presence of the secondary T790M mutation in exon 20. Preclinical data suggest that second-generation TKIs may be able to overcome T790M resistance by virtue of their irreversible mode of binding. In addition to the predominant mutations in the EGFR gene, alternative genetic changes between exons 18 and 21 have been observed. Experimental models have demonstrated that TKIs exhibit differential efficacy depending on which mutations are present. Such information may result in the design of highly specific agents that target specific mutations, which could result in more efficacious treatments.
Similar articles
-
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4416s-4420s. doi: 10.1158/1078-0432.CCR-06-0555. Clin Cancer Res. 2006. PMID: 16857820 Review.
-
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.Nat Genet. 2005 Dec;37(12):1315-6. doi: 10.1038/ng1671. Epub 2005 Oct 30. Nat Genet. 2005. PMID: 16258541
-
Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.Oncogene. 2009 Aug;28 Suppl 1:S14-23. doi: 10.1038/onc.2009.197. Oncogene. 2009. PMID: 19680292 Review.
-
Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4606-12. doi: 10.1158/1078-0432.CCR-07-0332. Clin Cancer Res. 2007. PMID: 17671150 Review.
-
Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.Cancer Res. 2007 Nov 1;67(21):10417-27. doi: 10.1158/0008-5472.CAN-07-1248. Cancer Res. 2007. PMID: 17974985
Cited by
-
KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations.Genes Cancer. 2011 Mar;2(3):335-43. doi: 10.1177/1947601911408080. Genes Cancer. 2011. PMID: 21779503 Free PMC article.
-
Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer.J Oncol. 2012;2012:986725. doi: 10.1155/2012/986725. Epub 2012 Mar 26. J Oncol. 2012. PMID: 22545054 Free PMC article.
-
A comparison of ARMS-Plus and droplet digital PCR for detecting EGFR activating mutations in plasma.Oncotarget. 2017 Dec 6;8(67):112014-112023. doi: 10.18632/oncotarget.22997. eCollection 2017 Dec 19. Oncotarget. 2017. PMID: 29340107 Free PMC article.
-
A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.Invest New Drugs. 2014 Dec;32(6):1226-35. doi: 10.1007/s10637-014-0139-9. Epub 2014 Jul 19. Invest New Drugs. 2014. PMID: 25037863 Clinical Trial.
-
Ethanol extract of Gleditsia sinensis thorn suppresses angiogenesis in vitro and in vivo.BMC Complement Altern Med. 2012 Dec 4;12:243. doi: 10.1186/1472-6882-12-243. BMC Complement Altern Med. 2012. PMID: 23206527 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous